Bioventus Inc (BVS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...

GuruFocus.com11-06

Revenue: $139 million, increased 15% compared to the prior year. Adjusted EBITDA: $24 million, increased by $2 million, representing an 8% increase compared to the prior year. Adjusted Gross Margin: ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481623395?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1c4QaViEuA.dE.gpBcOyOQ--~B/aD0xODA7dz0xODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/f770dc6b71b479d5db6163826ae8f6cd","is_english":true,"pubTime":"2024-11-06 15:14","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481623395","market":"us","top_or_hot":-1,"title":"Bioventus Inc (BVS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...","media":"GuruFocus.com","content":"<div>\n<p>Revenue: $139 million, increased 15% compared to the prior year.\nAdjusted EBITDA: $24 million, increased by $2 million, representing an 8% increase compared to the prior year.\nAdjusted Gross Margin: ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bioventus-inc-bvs-q3-2024-071456966.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bioventus Inc (BVS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioventus Inc (BVS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-06 15:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bioventus-inc-bvs-q3-2024-071456966.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenue: $139 million, increased 15% compared to the prior year.\nAdjusted EBITDA: $24 million, increased by $2 million, representing an 8% increase compared to the prior year.\nAdjusted Gross Margin: ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bioventus-inc-bvs-q3-2024-071456966.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BVS","symbol_name":"Bioventus Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/bioventus-inc-bvs-q3-2024-071456966.html","article_id":"2481623395","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1c4QaViEuA.dE.gpBcOyOQ--~B/aD0xODA7dz0xODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/f770dc6b71b479d5db6163826ae8f6cd"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481623395","pubTimestamp":1730877296,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Revenue: $139 million, increased 15% compared to the prior year.Adjusted EBITDA: $24 million, increased by $2 million, representing an 8% increase compared to the prior year.Adjusted Gross Margin: 75%, comparable to last year, down 10 basis points.Surgical Solutions Revenue: Increased by 18%, with both ultrasonics and bone graft substitutes showing double-digit growth.Pain Treatments Revenue: Increased by 18% compared to the prior year.Restorative Therapy Sales: Grew 6%, driven by accelerated growth from Exogen.International Segment Growth: 10% increase compared to the prior year.Adjusted Operating Income: Increased 2% to $21 million from $20 million in the prior year.Adjusted Net Income: $5 million, up 10% compared to the prior year.Adjusted Earnings Per Share: 6 for the quarter.Cash on Hand: $43 million, an increase of $11 million for the quarter.Debt Outstanding: $384 million, with $15 million drawn on the revolving credit facility.GuruFocus has detected 10 Warning Signs with BVS.Bi","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BVS":"Bioventus Inc."},"translate_title":"Bioventus Inc(BVS)2024年第三季度收益看涨期权亮点：强劲的收入增长和上调的指引……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BVS":1},"content_text":"Revenue: $139 million, increased 15% compared to the prior year.\nAdjusted EBITDA: $24 million, increased by $2 million, representing an 8% increase compared to the prior year.\nAdjusted Gross Margin: 75%, comparable to last year, down 10 basis points.\nSurgical Solutions Revenue: Increased by 18%, with both ultrasonics and bone graft substitutes showing double-digit growth.\nPain Treatments Revenue: Increased by 18% compared to the prior year.\nRestorative Therapy Sales: Grew 6%, driven by accelerated growth from Exogen.\nInternational Segment Growth: 10% increase compared to the prior year.\nAdjusted Operating Income: Increased 2% to $21 million from $20 million in the prior year.\nAdjusted Net Income: $5 million, up 10% compared to the prior year.\nAdjusted Earnings Per Share: 6 for the quarter.\nCash on Hand: $43 million, an increase of $11 million for the quarter.\nDebt Outstanding: $384 million, with $15 million drawn on the revolving credit facility.\nOperating Cash Flow: Inflow of $10 million despite a $9 million payment for shareholder litigation.\n2024 Net Sales Guidance: Increased to $562 million to $567 million.\n2024 Adjusted Earnings Per Share Guidance: Increased to 40 to 42.\n2024 Adjusted EBITDA Guidance: Unchanged, between $104 million and $107 million.\n\n\nWarning! GuruFocus has detected 10 Warning Signs with BVS.\n\nRelease Date: November 05, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nBioventus Inc (NASDAQ:BVS) reported a 15% revenue growth in the third quarter, marking the fourth consecutive quarter of double-digit organic revenue growth.\nThe company raised its full-year revenue guidance to the high end of previous expectations due to strong execution across all business segments.\nSurgical solutions saw accelerated double-digit growth, particularly in ultrasonics and bone graft substitutes, with strategic investments being made to further penetrate the market.\nThe HA business for knee osteoarthritis delivered double-digit growth, driven by significant demand for Dura Lane, and the company is confident in sustaining above-market growth.\nBioventus Inc (NASDAQ:BVS) generated positive cash flow from operations in the third quarter, increased its cash position, and reduced its net leverage ratio to approximately 3.5 turns.\n\n Negative Points \n\nThe company anticipates a short-term slowdown in bone graft substitutes growth due to earlier actions to delay adding new distributors and exiting some relationships.\nThere are unfavorable comps expected in Q4, particularly with Exogen, due to one-time favorability in the previous year.\nThe company faces temporary lag effects in ramping up new distributors for bone graft substitutes, which may affect the start of 2025.\nDespite strong performance, adjusted gross margin was slightly down by 10 basis points compared to the previous year.\nBioventus Inc (NASDAQ:BVS) is facing increased pressure from competitors in the HA market, which could impact future growth.\n\n Q & A Highlights \nQ: Can you provide more color on the 2024 guidance, particularly the implied 7% growth rate for Q4? Is there any seasonality or other factors affecting this? A: Robert Claypoole, CEO: We expect lower growth in Q4 due to unfavorable comps from last year, especially with Exogen, and a temporary slowdown in BGS growth due to earlier supply chain issues. However, we are confident in our continued momentum and expect approximately 13% top-line growth for the year.\nQ: How should we think about the pain treatments business in Q4, especially with competitors noting market headwinds? A: Mark Singleton, CFO: We expect to maintain momentum in Q4, driven by volume growth and our strong position with contracts and product differentiation. We don't foresee significant changes in our performance despite competitor activities.\nQ: Looking ahead to 2025, how are you thinking about growth and margin expansion? A: Robert Claypoole, CEO: While we won't provide specific guidance yet, we expect to continue our positive momentum with double-digit growth in ultrasonics and above-market growth in HA. We aim for over 100 basis points in EBITDA margin improvement and significant cash flow enhancement.\nQ: Are there any concerns about competitors refocusing on their HA business, potentially impacting your market share? A: Robert Claypoole, CEO: We have no concerns. Our strong clinical differentiation, dedicated sales force, and robust payer contracts position us well. We expect to continue growing above market despite increased competitive pressure.\nQ: Can you discuss the potential impact of new ultrasonic bone cutting tools in the market and your innovation plans? A: Robert Claypoole, CEO: We are early in the ultrasonic market with significant opportunities for expansion. We have a strong R&D team and plan to invest in innovation, which we'll update on in due course.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481623395"}